GP-2250 is under clinical development by Geistlich Pharma and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GP-2250’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GP-2250 overview

GP-2250 is under development for the treatment of pancreatic cancer, metastatic pancreatic adenocarcinoma, malignant peritoneal mesothelioma and ovarian cancer. It is administered through intravenous route. The drug candidate is a structural analog of taurultam (TRLT). The drug candidate acts by targeting glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Geistlich Pharma overview

Geistlich Pharma, a part of Geistlich Holding, is a pharmaceutical company that develops, manufactures, and markets biomaterials for the regeneration of bone, cartilage, and tissue. The company offers dental products, including bone substitutes, matrices, and membranes in various therapeutic areas such as bone augmentation, extraction socket management, sinus floor elevation, soft-tissue regeneration, peri-implantitis, and periodontal treatment. Its major products include Geistlich Bio-Oss, a natural bone substitute; and Geistlich Bio-Gide, a collagen membrane for oral tissue regeneration. It offers orthopedic products in various therapeutic areas such as bone substitutes and cartilage regeneration. Geistlich Pharma also offers dietary supplements, infectiology, and dermatology products. The company markets products through distribution partners and affiliates in Europe, Asia, South America, and North America. Geistlich Pharma is headquartered in Wolhusen, Switzerland.

For a complete picture of GP-2250’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.